drugset / Trial / NCT03823352
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
Timeline
- Start
- 2019-02-20
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Antroquinonol | Small molecule | 200 mg | Oral |
| Subject | Antroquinonol | Small molecule | 300 mg | Oral |